The zoonotic introductions and ongoing outbreaks of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) pose a global threat ([@R1],[@R2]) necessitating continuous serosurveillance to monitor virus spread alongside the development of vaccine and antibodies as countermeasures. Both approaches require validated assays to evaluate specific antibody responses. Although MERS-CoV serologic assays have been developed ([@R2]--[@R6]), those detecting functional antibodies cannot be applied in all laboratories and can require Biosafety Level 3 (BSL-3) containment. Recombinant protein-based immunoassays are easier to operate and standardize and do not require BSL-3 containment. However, MERS-CoV protein-based assays developed thus far can only detect antibody binding and give no information on antibody functionality. The MERS-CoV spike protein N terminal subunit (S1) contains 2 functional domains: the N-terminal domain (S1^A^), which binds sialic acid, the viral attachment factor; and the receptor-binding domain (RBD) (S1^B^), which binds dipeptidyl peptidase 4, the virus receptor ([@R7],[@R8]). Antibodies against those 2 domains can block MERS-CoV infection ([@R9]). Based on this fundamental knowledge, we developed 2 recombinant protein-based functional assays.

First, we developed an S1-based competitive ELISA, a receptor-binding inhibition assay (RBI), to test for antibodies that block the interaction with dipeptidyl peptidase 4, the viral receptor ([Appendix](#SD1){ref-type="local-data"} Figure 1). We validated the specificity of the assay for human diagnostics using serum samples from healthy blood donors, PCR-confirmed non--coronavirus-infected patients and non--MERS-CoV--infected patients (cohorts H1--H3) ([Appendix](#SD1){ref-type="local-data"} Table 1). At a 1/20 dilution, none of the samples from non--MERS-CoV-infected humans showed a [\>]{.ul}50% reduction in signal (RBI~50~) ([Figure](#F1){ref-type="fig"}, panel A), indicating a high specificity of the assay. MERS-CoV--specific RBI antibodies were detected in all the 90% plaque reduction neutralization assay (PRNT~90~)--positive serum samples of the PCR-confirmed MERS-CoV patients tested ([Appendix](#SD1){ref-type="local-data"} Table 2, Figure 2). The percentage reduction in signal strongly correlated with neutralizing antibody titers ([Figure](#F1){ref-type="fig"}, panel B). The RBI~50~ assay showed similar sensitivity to the PRNT~90~ assay.

![MERS-CoV--specific RBI and HI assays for MERS-CoV human diagnostics. A) Validation of the specificity of the RBI assay for the detection of MERS-CoV--specific antibodies in humans. Red dots indicate severe illness. Green dots indicate mild illness. B) Correlation between neutralizing and RBI antibody responses after MERS-CoV infection. C) Hemagglutination of turkey erythrocytes using S1^A^-nanoparticles. S1^A^-, S1^B^-, or empty self-assembling lumazine synthase nanoparticles were serially diluted and tested for the ablity to agglutinate turkey RBCs. D) Specificity of the HI assay for the detection of MERS-CoV S1^A^--directed antibodies. Rabbit anti-S1^A^, anti S1^B^, or anti-S1 serum samples were serially diluted and tested for the ability to block S1^A^-nanoparticles--induced hemagglutination of turkey RBCs. E) Validation of HI assay for the detection of MERS-CoV--specific antibodies in humans. F) Scatter plot correlating PRNT~90~ neutralization titers and HI titers after MERS-CoV infection. CoV, human coronavirus; HI, hemagglutination inhibition; MERS-CoV, Middle East respiratory syndrome coronavirus; PRNT~90~, 90% reduction in plaque reduction neutralization test; RBI, receptor-binding inhibition.](19-0921-F){#F1}

Because the RBI assay is species-independent, we validated its ability to detect RBI antibodies in dromedaries. At a 1/20 dilution, none of the naive dromedary serum samples ([@R10]) reacted in the assay, whereas all samples from MERS-CoV--infected dromedaries ([@R2]) resulted in a \>90% reduction in signal ([Appendix](#SD1){ref-type="local-data"} Table 1, Figure 3, panel A). We detected RBI antibodies in the samples of vaccinated and experimentally infected dromedaries ([Appendix](#SD1){ref-type="local-data"} Figure 3, panel B). Overall, the RBI~50~ was highly specific and showed comparable sensitivity to PRNT~90~ for detection of MERS-CoV--specific RBI (neutralizing) antibodies after infection and vaccination ([Appendix](#SD1){ref-type="local-data"} Figure 3, panel C).

Apart from the RBD, the MERS-CoV S1 contains an α2,3 sialic acid--binding S1^A^ domain ([@R7]). When this domain was multivalently presented on self-assembling lumazine synthase (LS) nanoparticles (S1^A^-Np), it was able to hemagglutinate human erythrocytes. To generate S1^A^-Np, we genetically fused the S1^A^ domain to LS and expressed the particles in HEK-293S cells ([Appendix](#SD1){ref-type="local-data"} Figure 4, panel A). By using S1^A^-Np, we developed a hemagglutination inhibition (HI) assay to detect antibodies capable of blocking virus interaction with sialic acids ([Appendix](#SD1){ref-type="local-data"} Figure 4, panel B). To set up the assay using turkey RBCs, we tested the ability of S1^A^-Np to agglutinate turkey erythrocytes by using empty (LS)-Np and S1^B^-Np as negative controls. Although neither the lumazine synthase--Np nor the S1^B^-Np showed any hemagglutination at any temperature tested, the S1^A^-Np induced hemagglutination at 4°C; we also noted hemagglutination when using dromedary erythrocytes ([Figure](#F1){ref-type="fig"}, panel C; [Appendix](#SD1){ref-type="local-data"} Figure 4, panel C). Although antibodies against the S1 and S1^A^ domain inhibited hemagglutination showing high HI titers, S1^B^ antibodies were negative for HI ([Figure](#F1){ref-type="fig"}, panel D).

Next, we used the same cohort of serum samples for validating the RBI assay. None of the samples from healthy blood donors, PCR-confirmed non--coronavirus-infected and non--MERS-CoV--infected patients (cohorts H1--H3) showed any HI at the 1/20 dilution ([Figure](#F1){ref-type="fig"}, panel E). HI antibodies were detected in the samples of all severely infected MERS-CoV patients and that of 1 mildly infected MERS-CoV patient ([Figure](#F1){ref-type="fig"}, panel E; [Appendix](#SD1){ref-type="local-data"} Figure 5); only 2 of the mildly infected MERS-CoV patients were PRNT~90~-positive ([Appendix](#SD1){ref-type="local-data"} Table 2). Serum HI titers correlated strongly with neutralizing antibody titers detected by a whole virus neutralization assay (PRNT~90~); nonetheless, the PRNT~90~ assay was more sensitive ([Figure](#F1){ref-type="fig"}, panel F). Similarly, only serum samples from MERS-CoV--infected dromedaries were HI-positive (10/13), whereas none of the naive dromedary camel serum samples showed any HI ([Appendix](#SD1){ref-type="local-data"} Figure 6, panel A). HI antibodies were detected in serum samples of vaccinated dromedaries after booster immunization ([Appendix](#SD1){ref-type="local-data"} Figure 6, panel B). Overall, although less sensitive, the antibody titers detected by the HI assay correlated strongly with the neutralizing antibody titers detected by PRNT~90~ assay ([Appendix](#SD1){ref-type="local-data"} Figure 6, panel C).

The RBI and HI assays we developed are easy to operate and standardize and can detect functional antibodies against 2 MERS-CoV S1 domains responsible for virus entry (RBD) and attachment (S1^A^). Both assays are protein-based and can be carried out in a 96-well plate format, therefore providing BSL-1 high-throughput platforms. The assays can be used as confirmatory assays for human and dromedary MERS-CoV diagnostics and for antibody and vaccine evaluation.

###### Appendix

Additional information about serologic detection of Middle East respiratory syndrome functional antibodies.
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